A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
Edwina N. Scott(University of Leicester), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Candice McCoy(Bayer (United States)), Anne Thomas(Leicester Royal Infirmary), Sarah P. Blagden(Churchill Hospital), L Rhoda Molife(Institute of Cancer Research), Kristin Kowal(Bayer (Germany)), W P Steward(University of Leicester), Herbert Wiesinger(Bayer (Germany)), Samreen Ahmed(University Hospitals of Leicester NHS Trust), Peter C.C. Fong(Royal Marsden NHS Foundation Trust)
Cited by 34
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k